1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

Iksuda Aims For Best-In-Class Cancer ADCs With Toolbox Approach To Technology

 
• By Ayisha Sharma

Emerging Company Profile: While the UK biotech boasts a promising in-house platform technology, it believes a less restrictive approach to R&D could help it develop superior antibody-drug conjugates for cancer.  

Emerging Company Profile: Iksuda Therapeutics
PermaLink Can Design ADCs That Are Insusceptible To De-Conjugation • Source: Shutterstock
Key Takeaways:

  • Iksuda’s PermaLink technology can design ADCs insusceptible to drug de-conjugation.

Iksuda Therapeutics is on mission to design and develop more securely conjugated and efficacious antibody-drug conjugates (ADCs) for the treatment of cancers and is taking a liberated approach to using technology.

The UK firm’s story goes back to 2007 when investor IP Group founded a company called Glythera with two platforms...

More from Emerging Company Profiles

More from Start-Ups & SMEs